PL1686984T3 - Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowych - Google Patents

Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowych

Info

Publication number: PL1686984T3
Authority: PL; Poland
Prior art keywords: cyclohexyl; dimethylaminomethyl; phenol; methoxyphenyl; phenyl
Prior art date: 2003-11-28

Application number

PL04819227T

Other languages

English (en)

Inventor

Petra Bloms-Funke

Werner Englberger

Hagen-Heinrich Hennies

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-28

Filing date

2004-11-26

Publication date

2011-10-31

2004-11-26 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2011-10-31 Publication of PL1686984T3 publication Critical patent/PL1686984T3/pl

Links

208000019901 Anxiety disease Diseases 0.000 title abstract 3
JIRYWFYYBBRJAN-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]cyclohexyl]phenol Chemical compound CN(C)CC1CCCCC1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-UHFFFAOYSA-N 0.000 abstract 5
239000000935 antidepressant agent Substances 0.000 abstract 3
229940005513 antidepressants Drugs 0.000 abstract 3
VTXTVLAQPBIPPF-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=CC(C2C(CCCC2)CN(C)C)=C1 VTXTVLAQPBIPPF-UHFFFAOYSA-N 0.000 abstract 2
239000002671 adjuvant Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
LOMMOGHGUYMOEF-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine oxide Chemical compound COC1=CC=CC(C2C(CCCC2)C[N+](C)(C)[O-])=C1 LOMMOGHGUYMOEF-UHFFFAOYSA-N 0.000 abstract 1
WMFQEDGHYPJQSG-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n-methylmethanamine Chemical compound CNCC1CCCCC1C1=CC=CC(OC)=C1 WMFQEDGHYPJQSG-UHFFFAOYSA-N 0.000 abstract 1
-1 3-(2-dimethylaminomethyl-cyclohexyl)-phenol N-oxide Chemical class 0.000 abstract 1
WMRBLCTVXONZBT-UHFFFAOYSA-N 3-[2-(aminomethyl)cyclohexyl]phenol Chemical compound NCC1CCCCC1C1=CC=CC(O)=C1 WMRBLCTVXONZBT-UHFFFAOYSA-N 0.000 abstract 1
KUGOVDMEUQXLRD-UHFFFAOYSA-N 3-[2-(methylaminomethyl)cyclohexyl]phenol Chemical compound CNCC1CCCCC1C1=CC=CC(O)=C1 KUGOVDMEUQXLRD-UHFFFAOYSA-N 0.000 abstract 1
CKMPEIWYGQTXJB-UHFFFAOYSA-N 4-[2-[(dimethylamino)methyl]cyclohexyl]benzene-1,2-diol Chemical compound CN(C)CC1CCCCC1C1=CC=C(O)C(O)=C1 CKMPEIWYGQTXJB-UHFFFAOYSA-N 0.000 abstract 1
FMGWPVLPVFJEAH-UHFFFAOYSA-N 6-[3-[2-[(dimethylamino)methyl]cyclohexyl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CN(C)CC1CCCCC1C1=CC=CC(OC2C(C(O)C(O)C(O2)C(O)=O)O)=C1 FMGWPVLPVFJEAH-UHFFFAOYSA-N 0.000 abstract 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
NPZGGTZKFXTTSR-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]cyclohexyl]phenyl] hydrogen sulfate Chemical compound CN(C)CC1CCCCC1C1=CC=CC(OS(O)(=O)=O)=C1 NPZGGTZKFXTTSR-UHFFFAOYSA-N 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
229940126569 noradrenaline reuptake inhibitor Drugs 0.000 abstract 1
230000000966 norepinephrine reuptake Effects 0.000 abstract 1
239000003402 opiate agonist Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000000697 serotonin reuptake Effects 0.000 abstract 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL04819227T 2003-11-28 2004-11-26 Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowych PL1686984T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10356362A DE10356362A1 (de)	2003-11-28	2003-11-28	Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen
EP04819227A EP1686984B1 (de)	2003-11-28	2004-11-26	Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen
PCT/EP2004/013439 WO2005051375A1 (de)	2003-11-28	2004-11-26	Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen

Publications (1)

Publication Number	Publication Date
PL1686984T3 true PL1686984T3 (pl)	2011-10-31

Family

ID=34609453

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL08008351T PL1970060T3 (pl)	2003-11-28	2004-11-26	Zastosowanie związków C-(2-fenylocykloheksylo)-metylo-aminowych do terapii fibromyalgii
PL04819227T PL1686984T3 (pl)	2003-11-28	2004-11-26	Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL08008351T PL1970060T3 (pl)	2003-11-28	2004-11-26	Zastosowanie związków C-(2-fenylocykloheksylo)-metylo-aminowych do terapii fibromyalgii

Country Status (14)

Country	Link
US (3)	US20060258741A1 (pl)
EP (2)	EP1970060B9 (pl)
JP (1)	JP5013875B2 (pl)
AT (1)	ATE509626T1 (pl)
CA (1)	CA2546672C (pl)
CY (2)	CY1113348T1 (pl)
DE (1)	DE10356362A1 (pl)
DK (2)	DK1686984T3 (pl)
ES (2)	ES2390931T3 (pl)
HR (1)	HRP20110608T1 (pl)
PL (2)	PL1970060T3 (pl)
PT (2)	PT1970060E (pl)
SI (2)	SI1686984T1 (pl)
WO (1)	WO2005051375A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050182131A1 (en) *	2002-07-19	2005-08-18	Gruenenthal Gmbh	1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence
DE102005034974A1 (de) *	2005-07-22	2007-04-19	Grünenthal GmbH	Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
DE102005034973A1 (de) *	2005-07-22	2007-02-15	Grünenthal GmbH	Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
DE102005061428A1 (de) *	2005-12-22	2007-08-16	Grünenthal GmbH	Substituierte Cyclohexylmethyl-Derivate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19525137C2 (de) *	1995-07-11	2003-02-27	Gruenenthal Gmbh	6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
US6387956B1 (en) *	1999-03-24	2002-05-14	University Of Cincinnati	Methods of treating obsessive-compulsive spectrum disorders
DE10059411A1 (de) *	2000-11-30	2002-06-13	Gruenenthal Gmbh	Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz
DE10109763A1 (de) *	2001-02-28	2002-09-05	Gruenenthal Gmbh	Pharmazeutische Salze
DE10146275A1 (de) *	2001-09-18	2003-04-24	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
WO2003048113A1 (en) *	2001-11-30	2003-06-12	Sepracor Inc.	Tramadol analogs and uses thereof
DE10233048A1 (de) *	2002-07-19	2004-01-29	Grünenthal GmbH	Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken
DK3241550T3 (da) *	2002-11-22	2020-08-24	Gruenenthal Gmbh	Anvendelse af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol til behandling af inflammatoriske smerter
DE10254785A1 (de) *	2002-11-22	2004-06-03	Grünenthal GmbH	Kombination ausgewählter Analgetika mit COX II-Inhibitoren
DE102005011517A1 (de) *	2005-03-10	2006-09-21	Grünenthal GmbH	Transdermales therapeutisches System zur Verabreichung von Analgetika
US20090104266A1 (en) *	2005-09-15	2009-04-23	Tobias Jung	3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation

2003
- 2003-11-28 DE DE10356362A patent/DE10356362A1/de not_active Ceased
2004
- 2004-11-26 AT AT04819227T patent/ATE509626T1/de active
- 2004-11-26 PL PL08008351T patent/PL1970060T3/pl unknown
- 2004-11-26 PT PT08008351T patent/PT1970060E/pt unknown
- 2004-11-26 DK DK04819227.2T patent/DK1686984T3/da active
- 2004-11-26 PL PL04819227T patent/PL1686984T3/pl unknown
- 2004-11-26 CA CA2546672A patent/CA2546672C/en not_active Expired - Fee Related
- 2004-11-26 ES ES08008351T patent/ES2390931T3/es not_active Expired - Lifetime
- 2004-11-26 DK DK08008351.2T patent/DK1970060T3/da active
- 2004-11-26 SI SI200431677T patent/SI1686984T1/sl unknown
- 2004-11-26 EP EP08008351A patent/EP1970060B9/de not_active Expired - Lifetime
- 2004-11-26 HR HR20110608T patent/HRP20110608T1/hr unknown
- 2004-11-26 JP JP2006540395A patent/JP5013875B2/ja not_active Expired - Fee Related
- 2004-11-26 ES ES04819227T patent/ES2362752T3/es not_active Expired - Lifetime
- 2004-11-26 WO PCT/EP2004/013439 patent/WO2005051375A1/de not_active Ceased
- 2004-11-26 SI SI200431926T patent/SI1970060T1/sl unknown
- 2004-11-26 PT PT04819227T patent/PT1686984E/pt unknown
- 2004-11-26 EP EP04819227A patent/EP1686984B1/de not_active Expired - Lifetime
2006
- 2006-05-25 US US11/440,005 patent/US20060258741A1/en not_active Abandoned
2009
- 2009-09-14 US US12/558,896 patent/US8084497B2/en not_active Expired - Fee Related
2010
- 2010-06-09 US US12/797,408 patent/US20100249225A1/en not_active Abandoned
2011
- 2011-06-21 CY CY20111100588T patent/CY1113348T1/el unknown
2012
- 2012-09-28 CY CY20121100904T patent/CY1113162T1/el unknown

Also Published As

Publication number	Publication date
SI1686984T1 (sl)	2011-07-29
US20100004341A1 (en)	2010-01-07
ES2362752T3 (es)	2011-07-12
ATE509626T1 (de)	2011-06-15
US20100249225A1 (en)	2010-09-30
DK1970060T3 (da)	2012-10-01
JP2007512288A (ja)	2007-05-17
EP1686984B1 (de)	2011-05-18
HRP20110608T1 (hr)	2011-10-31
EP1970060B1 (de)	2012-08-29
PT1970060E (pt)	2012-10-02
US8084497B2 (en)	2011-12-27
DK1686984T3 (da)	2011-06-20
ES2390931T3 (es)	2012-11-19
EP1970060B9 (de)	2013-01-09
EP1970060A2 (de)	2008-09-17
CA2546672A1 (en)	2005-06-09
PL1970060T3 (pl)	2012-11-30
JP5013875B2 (ja)	2012-08-29
CY1113348T1 (el)	2016-06-22
US20060258741A1 (en)	2006-11-16
DE10356362A1 (de)	2005-06-23
SI1970060T1 (sl)	2012-10-30
CA2546672C (en)	2013-01-22
WO2005051375A1 (de)	2005-06-09
PT1686984E (pt)	2011-05-30
EP1970060A3 (de)	2009-04-15
EP1686984A1 (de)	2006-08-09
CY1113162T1 (el)	2016-04-13

Publication	Publication Date	Title
US6001884A (en)	1999-12-14	Calcium receptor-active molecules
CA2173747C (en)	2006-05-23	Calcium receptor-active arylalkyl amines
PL2010531T3 (pl)	2011-12-30	Spirocykliczne pochodne cykloheksanu o działaniu przeciwbólowym
CY1113162T1 (el)	2016-04-13	Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων
EP0787122A2 (en)	1997-08-06	Calcium receptor-active compounds
JP2007523955A (ja)	2007-08-23	疾患の治療のためのアミンおよびアミド
RU2007139543A (ru)	2009-05-27	Производные бензодиоксана и бензодиоксолана и их применение
AU2010236404A1 (en)	2011-11-10	Monoamine reuptake inhibitors
CA2722776A1 (en)	2009-11-12	Nmda receptor antagonists for the treatment of neuropsychiatric disorders
RS50538B (sr)	2010-05-07	Sulfonamidni derivati namenjeni lečenju bolesti
EP2104503A1 (en)	2009-09-30	Morpholine dopamine agonists for the treatment of pain
EA200800430A1 (ru)	2008-06-30	Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
JP2012144545A (ja)	2012-08-02	アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
BG106912A (bg)	2003-01-31	Дифенилетерни съединения, приложими в терапията
EP1824837B1 (en)	2008-08-13	Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
EP4161900A1 (en)	2023-04-12	Cannabidiolic acid (cbda) derivatives and uses thereof
JP2012036212A (ja)	2012-02-23	ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
JP5714580B2 (ja)	2015-05-07	３−フェノキシメチルピロリジン化合物
CA2492876A1 (en)	2004-01-29	1-phenyl-2-dimethylaminomethylcyclohexane compounds for therapy of depressive symptoms, pain, and incontinence
JP2013522363A (ja)	2013-06-13	１−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
EP1791599A1 (en)	2007-06-06	Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
EP3455203A1 (en)	2019-03-20	Vinylogous phenethylamines as neurotransmitter releasers
HK1012620B (en)	2005-01-14	Calcium receptor-active arylalkyl amines
HK1070351A (en)	2005-06-17	Calcium receptor-active arylalkyl amines
AU3122699A (en)	1999-07-22	Calcium receptor active arylakyl amines